Oligonucleotide Synthesis - Global Size, Share, Trends, Analysis and Forecast 2022 – 2026
                     MarketsandMarkets 
Presents
Oligonucleotide Synthesis Market worth $14.1 billion by 2026
https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200
829350.html
The report "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos 
(Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, 
siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global 
Forecast to 2026", is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion 
in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the 
growth of this market include the increasing use of synthesized oligos in therapeutic 
applications, increasing government funding, and the growing focus on personalized 
medicine.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownload
Objectives of the Study:
• The hospital segment accounted for the largest share of the end user segment in 
the oligonucleotide synthesis
• The PCR sub segment accounted for the largest share of the research application 
segment
• The Asia Pacific region is the fastest growing region
In 2020, the Asia Pacific region accounted for the fasted growing region of 
the oligonucleotide synthesis market. Factors such as growing R&D 
funding, rising product availability, lower outsourcing costs, increasing 
research activities, increasing applications of oligos in molecular 
diagnostics & therapeutics, and the rising awareness of oligonucleotides 
are expected to drive market growth.
Speak to Analyst: https://www.marketsandmarkets.com/
The study categorizes the oligonucleotide synthesis market into the 
following segments and subsegments:
Oligonucleotide synthesis Market, by Product
• Oligonucleotide-based Drugs
• Synthesized Oligonucleotides
• By Product
• Primers
• Probes
• DNA Oligos
• RNA Oligos
• Other Synthesized Oligos
• By Type
• Customized Oligos
• Predesigned Oligos
• Reagents
• Equipment
Oligonucleotide synthesis Market, by Application 
• Research Applications
• PCR
• Sequencing
• Other Research Applications
• Diagnostic Applications
Some of the leading players operating in the oligonucleotide synthesis market are 
Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), 
LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The 
leading players in the oligonucleotide therapeutics market are Biogen Inc. (US) and 
Sarepta Therapeutics, Inc. (US).
Companies Insight
Danaher is one of the key players in the oligonucleotide synthesis market, owing to its robust 
product portfolio and brand recognition. The two largest acquisitions of IDT (US) and Cytiva (US) 
enhanced Danaher’s oligonucleotide product offering. The company now offers synthesized 
oligos such as primers & probes and the raw materials used to synthesize oligos such as reagents 
and equipment. Danaher’s key growth strategy is introducing active product launches. For 
instance, in 2019, the company launched the longest (up to 350 mers in length), high quality, 
and ready-to-use custom oligo pools in the market. Such strategic developments help the 
company sustain its position in the oligonucleotide synthesis market.
Thermo Fisher Scientific (US) led the oligonucleotide synthesis market with a share of 21.4% in 
2020. The company has an exhaustive product portfolio consisting of primers, probes, custom 
oligos, phosphoramidites, reagents, and custom oligo modification. It has adopted various 
organic and inorganic growth strategies to strengthen its market position. For instance, in 2019, 
Thermo Fisher supported BioNTechs (Germany) messenger RNA (mRNA) manufacturing platform 
by supplying nucleotides, enzymes, reagents, and other critical raw materials to expand their 
manufacturing capacities. Despite the pandemic, the company witnessed a substantial increase 
in the revenue of its Life Sciences segment as compared to 2019. Increasing revenues in the 
company’s business were primarily driven by the demand for COVID-19 testing with higher sales 
of bioproduction products and genetic sciences, which include oligonucleotide products.
Contact Us
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road, Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
Press release:
https://www.marketsandmarkets.com/PressReleases/oligonucleotide-
synthesis.asp
Research insights:
https://www.marketsandmarkets.com/ResearchInsight/oligonucleotid
e-synthesis-market.asp
About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche 
opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. 
Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 
companies as clients. Almost 75,000 top officers across eight industries worldwide 
approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high 
growth markets following the "Growth Engagement Model – GEM". The GEM aims at 
proactive collaboration with the clients to identify new opportunities, identify most 
important customers, write "Attack, avoid and defend" strategies, identify sources of 
incremental revenues for both the company and its competitors. MarketsandMarkets™ 
now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, 
emerging companies, innovators, strategic players) annually in high growth emerging 
segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies 
this year for their revenue planning and help them take their innovations/disruptions 
early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, 
"RT" connects over 200,000 markets and entire value chains for deeper understanding 
of the unmet insights along with market sizing and forecasts of niche markets.